Inhibitors of PI3K/ERK1/2/p38 MAPK Show Preferential Activity Against Endocrine-Resistant Breast Cancer Cells

Current mainstream pharmacological options for the treatment of endocrine-resistant breast cancer have limitations in terms of their side effect profile and lack of discrimination between normal and cancer cells. In the current study, we assessed the responses of normal breast epithelial cells MCF10...

Descripción completa

Detalles Bibliográficos
Autores principales: Khajah, Maitham A., Mathew, Princy M., Luqmani, Yunus A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841054/
https://www.ncbi.nlm.nih.gov/pubmed/28276317
http://dx.doi.org/10.3727/096504017X14883245308282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841054/
https://www.ncbi.nlm.nih.gov/pubmed/28276317
http://dx.doi.org/10.3727/096504017X14883245308282

Ejemplares similares